Associations of renal dysfunction and hyperuricemia in patients with a new coronavirus infection

The purpose: to study the association of hyperuricemia and renal dysfunction in convalescents of new coronavirus infection. Materials and methods: The study included 234 people who had a new coronavirus infection COVID-19 and were observed two months after convalescence. The mean age was 54.10±12.88 years. Three groups of patients were formed according to the anamnesis according to the severity of the new coronavirus infection: mild (n=108), moderate (n=112), and severe (n=14). In patients, BMI, creatinine, and uric acid levels were determined. Statistical processing of the obtained results was performed using the SPSS software package. Results: the average level of GFR was 80.34±16.66 ml/min/1.73 m2. In patients with a mild course of coronavirus infection, the average GFR was 82.52±15.78 ml/min/1.73 m2, with a moderate course - 78.33±17.69 ml/min/1.73 m2, with a severe course - 79.71±13.38 ml/min/1.73 m2. А decrease in GFR below 90 ml/min/1.73 m2 occurred in 69.3% of cases. Significant differences were obtained between the 1st and 2nd groups (p=0.046). Hyperuricemia was registered in 33.8% of cases. Moreover, in patients with a severe course of coronavirus infection, hyperuricemia was more common than in those with a mild course (64.3% vs 26.4%, p=0.0001) and those with a moderate course (64.3% vs 31.8%, p=0.002). Decreased GFR in patients with a mild form of COVID-19 is associated with the presence of hyperglycemia. In addition, an increase in BMI by 1 kg/m2 leads to a 10% reduction in the risk of developing renal dysfunction. In patients who had moderate COVID-19, a decrease in GFR was associated only with hyperuricemia. Conclusion: hyperuricemia is observed in 33.8% of patients 2 months after a new coronavirus infection. A decrease in GFR of less than 60 ml/min/1.73 m2 was observed in 10% of patients. Hyperuricemia is directly related to the severity of COVID-19 infection. The causal relationship between hyperuricemia in patients after COVID-19 and impaired renal function requires further research.

COVID-19, SARS-CoV-2, гиперурикемия, почечная дисфункция, хроническая болезнь почек, компоненты метаболического синдрома, COVID-19, SARS-CoV-2, hyperuricemia, renal dysfunction, chronic kidney disease, metabolic syndrome components

1. World Health Organization. COVID-19 Weekly Epidemiological Update. Edition 60, published 5 October 2021. Situation Reports.

2. Dawei W., Bo Hu, Chang Hu. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17; 323(11): 1061-1069. DOI:10.1001/jama.2020.1585.

3. Grasselli G., Zangrillo A., Zanella A. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16): 1574-1581. doi:10.1001/jama.2020.5394.

4. Chow N., Fleming-Dutra K., Gierke G. et al. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States. February 12-March 28. Weekly. 2020; 69(13); 382-386. doi:10.15585/mmwr.mm6913e2.

5. Major R.W., Cheng M.R.I., Grant R.A. et al. Сardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2018; 13(3): e0192895. doi: 10.1371/journal.pone.0192895Klinicheskiye rekomendatsii.

6. Hill N.R., Fatoba S.T., Oke J.L. et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(7): e0158765. doi: 10.1371/journal.pone.0158765.

7. Johnson R.J., Nakagawa T., Jalal D. et al. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013; 28(9): 2221-8. doi: 10.1093/ndt/gft029.

8. Li L., Yang C., Zhao Y. et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014; 15: 122. doi: 10.1186/1471-2369-15-122.

9. Xia X., Luo Q., Li B. et al. Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2016; 65(9): 1326-41. doi: 10.1016/j.metabol.2016.05.009.

10. Liu Y. M., Xie J., Chen M.M., et al. Kidney Function Indicators Predict Adverse Outcomes of COVID-19. Med (NY). 2021; 2(1): 38-48. e2. doi: 10.1016/j.medj.2020.09.001.

11. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension. 2018; 36(10): 1953-2041. doi: 10.1097/HJH.0000000000001940.

12. Кобалава Ж.Д., Конради А.О., Недогода С.В., и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(3): 149-218. doi:10.15829/1560-4071-2020-3-3786.

13. Sevajol M., Subissi L., Decroly E. et al. Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus. Virus Research. 2014; 194: 90-99. doi: 10.1016/j.virusres.2014.10.008.

14. Hanley B., Naresh K.N., Roufosse C. et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020; 1(6): e245-e253. doi: 10.1016/S2666-5247(20)30115-4.

15. Chaolin H., Lixue H., Yeming W. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397(10270): 220-232. doi: 10.1016/S0140-6736(20)32656-8.

16. Ishii M., Terai H., Kabata H. et al. Keio COVID-19 Research Consortium (K-CORC) and the Keio Donner Project Team. Clinical characteristics of 345 patients with coronavirus disease 2019 in Japan: A multicenter retrospective study. J Infect. 2020; 81(5): e3-e5. doi: 10.1016/j.jinf.2020.08.052.

17. Tsuchihashi Y., Arima Y., Takahashi T. et al. Clinical Characteristics and Risk Factors for Severe Outcomes of Novel Coronavirus Infection, January-March 2020, Japan. J Epidemiol. 2021; 31(8): 487-494. doi: 10.2188/jea.JE20200519.

18. Chen B., Lu C., Gu H.Q. et al. Serum Uric Acid Concentrations and Risk of Adverse Outcomes in Patients With COVID-19. Front Endocrinol (Lausanne). 2021; 12: 633767. doi: 10.3389/fendo.2021.633767.

19. Hu F., Guo Y., Lin J. et al. Association of serum uric acid levels with COVID-19 severity. BMC EndocrDisord. 2021; 21(1): 97. doi: 10.1186/s12902-021-00745-2.

20. Jing Liang J., Liu J., Chen Y. et al. Characteristics of laboratory findings of COVID-19 patients with comorbid diabetes mellitus. Diabetes Res ClinPract. 2020; 167:108351. doi: 10.1016/j.diabres.2020.108351.

21. Werion A., Belkhir L., Perrot M. et al. Cliniques universitaires Saint-Luc (CUSL) COVID-19 Research Group. SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. Kidney Int. 2020; 98(5): 1296-1307. doi: 10.1016/j.kint.2020.07.019.

22. Câmara N.O., Iseki K., Kramer H. et al. Kidney disease and obesity: epidemiology, mechanisms and treatment. Nat Rev Nephrol. 2017; 13(3): 181-190. doi: 10.1038/nrneph.2016.191.

23. Zhang J., Jiang H., Chen J. Combined effect of body mass index and metabolic status on the risk of prevalent and incident chronic kidney disease: a systematic review and meta-analysis. Oncotarget. 2017; 8(22): 35619-35629. doi: 10.18632/oncotarget.10915.

24. Sahin S., Sezer H., Cicek E. et al. The Role of Obesity in Predicting the Clinical Outcomes of COVID-19. Obes Facts. 2021; 14(5): 481-489. doi: 10.1159/000517180.